Search

Dimetindene

Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

Midostaurin

It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

Technetium Tc-99m nofetumomab merpentan

It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.

Ethylenediamine

It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

Bovine type I collagen

It plays a vital role in cell growth, differentiation, attachment, and migration [L2481]. … Bovine collagen alpha-1 is a naturally occurring extracellular matrix protein which is found in tendons and other connective tissues.

Donanemab

[A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that

Vaborbactam

[A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. … Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.

Glatiramer

[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.

Citrus bioflavonoids

Ocrelizumab

It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].